At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Nov 4, 2026 at 07:05 ET
The headline event is the FDA's acceptance of the BLA for AMT-130 in Huntington's disease under Priority Review, with a PDUFA date of May 1, 2027, and alignment on a confirmatory study design. Cash of $768.4M funds operations into 2030.
- FDA granted Priority Review for AMT-130 BLA; PDUFA target May 1, 2027
- Q3 2026 revenue $5.2M vs. consensus $5.4M (beat by 3.7%)
- Cash, equivalents and securities $768.4M as of Sep 30, 2026; runway into 2030
- Confirmatory study design aligned with FDA: ~200 patients, 2:1 randomization, TFC primary endpoint at 36 months; screening starts by end of 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access